More on GALT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.0 Score)
- Holders

Upcoming Events

- Earnings (8/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Galectin Therapeutics (NQ:GALT)
Delayed: 3.33 -0.14 (4.03%)
Prev. Close $3.47  
Open$3.50 
52 Wk High$3.05 
52 Wk Low$0.49 
Day High$3.58 
Day Low$3.33 
P/E N/A  
EPS$-1.32 
Volume144,721 


Jul 16, 2026 05:40 PM Form 4 GALECTIN THERAPEUTICS For: Jul 14 Filed by: Jamil Khurram
Jun 30, 2026 07:24 PM Form 4 GALECTIN THERAPEUTICS For: Jun 26 Filed by: Shlevin Harold H.
Jun 30, 2026 07:23 PM Form 4 GALECTIN THERAPEUTICS For: Jun 26 Filed by: Jamil Khurram
Jun 29, 2026 04:10 PM Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.
Jun 26, 2026 06:09 PM Form 144 GALECTIN THERAPEUTICS Filed by: Jamil Khurram
Jun 26, 2026 04:16 PM Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.
Jun 25, 2026 04:06 PM Form 4 GALECTIN THERAPEUTICS For: Jun 23 Filed by: Jamil Khurram
Jun 23, 2026 04:15 PM Form 144 GALECTIN THERAPEUTICS Filed by: Jamil Khurram
Jun 23, 2026 08:00 AM Galectin reaches FDA agreement on belapectin Phase 3 trial design
Jun 23, 2026 08:00 AM Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
View All Articles

Entities mentioned with GALT

View All Entities